Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival

Journal of the American College of Cardiology

Volumn 40, Issue 4, 2002, Pages 780-788

  Sitbon, Olivier ^a   Humbert, Marc ^a   Nunes, Hilario ^a   Parent, Florence ^a   Garcia, Gilles ^a   Hervé, Philippe ^a   Rainisio, Maurizio ^a   Simonneau, Gérald ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; EXERCISE; FEMALE; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FAILURE; HEMANGIOMATOSIS; HEMODYNAMICS; HUMAN; LEG PAIN; LUNG ARTERY PRESSURE; LUNG CAPILLARY; LUNG EDEMA; LUNG RESISTANCE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME; VEIN OCCLUSION; VOMITING;

ADULT; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0037151645     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02012-0     Document Type: Article

References (20)

1. Primary pulmonary hypertension: A national prospective study
2. Survival in patients with primary pulmonary hypertension: Results from a national prospective study
3. Primary pulmonary hypertension
4. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension
5. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
6. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
7. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
8. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
9. Primary pulmonary hypertension: Case series from France
10. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
11. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: A dose-response study and comparison with prostacyclin
12. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis
13. Survival in primary pulmonary hypertension: Validation of a prognostic equation
14. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
15. Bosentan therapy for pulmonary arterial hypertension
16. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: Comparison with cardiopulmonary exercise testing
17. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades
18. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and in rat lung via cAMP
19. Improvement of the pressure flow relationships of the pulmonary circulation in primary pulmonary hypertension after six weeks prostacyclin